|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.38 - 2.68|
|52 Week Range||0.81 - 3.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Clarence, New York-based company said it had a loss of 3 cents per share. The plant biotechnology company posted revenue of $4.5 million in the period. In the final minutes of trading on Thursday, ...
22nd Century Group Inc (AMEX:XXII) is a small-cap stock with a market capitalization of USD $270.56M. While investors primarily focus on the growth potential and competitive landscape of the small-capRead More...
22nd Century Group Inc (AMEX:XXII), a tobacco company based in United States, received a lot of attention from a substantial price movement on the AMEX in the over the lastRead More...
It's still the best-performing marijuana stock of the year, but a recent plunge puts its reign at the top in jeopardy.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for 22nd Century Group, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)
If you're on the hunt for small-cap biotechs that could be big winners next year, Amarin, MannKind Corp., and 22nd Century Group need to be on your radar right now.
In a recent article, Tyler Stratford, director of client operations at Canna Advisors, one of the top cannabis consulting firms in North America, shared a few fundamental tips for obtaining a marijuana ...
How powerful are Mexican drug cartels? What would a legal cannabis trade between the U.S. and its southern neighbor look like? Very few people are actually qualified to answer such questions. Luckily for ...
The legal cannabis industry is growing at an unprecedented pace, and jobs continue to pop up like crazy, creating opportunities of all kinds. This is an industry that loves the Wall Street executive as ...
Investors are responding to claims this tiny company will become the king of a soon-to-exist market for non-addictive tobacco.
The FDA is considering mandating that cigarette nicotine levels drop to the point that they aren't addictive. The thinking is that low-nicotine cigarettes would drive smokers to non-combustible sources of nicotine, such as e-cigarettes, which are thought to be safer. But would that be the case?
Investors are betting on a little-known biotech company to supply Big Tobacco with low-nicotine cigarettes, but so far its technology is unproven. Shares in New York-based 22nd Century Group have soared 80 percent to a three-year high since late last month, when the U.S. Food and Drug Administration proposed cutting the nicotine levels in cigarettes so they aren't so addictive. Investors' hopes are pinned on 22nd Century's technology becoming widespread, although none of the big tobacco makers has bought it yet.
An obscure biotechnology company in western New York with about 80 employees suddenly saw its popularity rise last week after the tobacco industry was shocked by an announcement the federal government ...